INMB
Inmune Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.54
−1.91%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.15
- Revenue estimate
- $1.9M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.21
- Revenue actual
- —
- Revenue estimate
- $1.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +36.9%
- Revenue beats (12Q)
- 1
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.21 | -$0.05 | Beat 75.81% | — |
| May 7, 2026 | -$0.24 | -$0.20 | Beat 18.37% | — |
| Mar 30, 2026 | -$0.26 | -$0.18 | Beat 30.77% | — |
| Oct 30, 2025 | -$0.31 | -$0.24 | Beat 22.58% | — |
| Aug 7, 2025 | -$0.37 | -$0.34 | Beat 8.11% | — |
| May 8, 2025 | -$0.43 | -$0.43 | In line | $50.0K |
| Mar 27, 2025 | -$0.54 | -$0.40 | Beat 25.93% | — |
| Oct 31, 2024 | -$0.49 | -$0.60 | Miss -22.45% | — |
| Aug 1, 2024 | -$0.63 | -$0.50 | Beat 20.63% | — |
| May 9, 2024 | -$0.53 | -$0.61 | Miss -15.09% | $14.0K |
| Nov 1, 2023 | -$0.39 | -$0.48 | Miss -23.08% | $43.0K |
| May 3, 2023 | -$0.02 | -$0.36 | Miss -1700.00% | $38.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026